Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-11-06
2007-11-06
Weber, Jon (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S814000, C514S832000, C514S921000, C514S930000, C530S385000, C530S402000, C530S829000, C424S529000, C424S533000
Reexamination Certificate
active
10678927
ABSTRACT:
Methods for treating a mammal suffering from massive blood loss comprising administering to the mammal a polymerized hemoglobin solution.
REFERENCES:
patent: 4826811 (1989-05-01), Sehgal et al.
patent: 5084558 (1992-01-01), Rausch et al.
patent: 5464814 (1995-11-01), Sehgal et al.
patent: 5691452 (1997-11-01), Gawryl et al.
patent: 5691453 (1997-11-01), Wirtz et al.
patent: 5840852 (1998-11-01), Rausch et al.
patent: 5895810 (1999-04-01), Light et al.
patent: 5955581 (1999-09-01), Rausch et al.
patent: 6150507 (2000-11-01), Houtchens et al.
patent: 6271351 (2001-08-01), Gawryl et al.
patent: 6288027 (2001-09-01), Gawryl et al.
patent: 6323320 (2001-11-01), Sehgal et al.
patent: 6498141 (2002-12-01), DeWoskin et al.
patent: 2002/0065211 (2002-05-01), Jacobs, Jr. et al.
Gould, S.A., et al.,The Life-Sustaining Capacity of Human Polymerized Hemoglobin when Red Cells Might Be Unavailable, Journal of the American College of Surgeons, 195 (4): 445-455 (Oct. 2002).
Carson, J.L., et al.,Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion, Transfusion, 42: 812-818 (Jul. 2002).
Moore, F.A., et al.,Trauma Resuscitation, ACS Surgery- Principles & Practice, 31-61 (2002).
American College of Surgeons Committee on Trauma. Advanced Trauma Life Support Program for Physicians 1997 Instructional Manual, 6th, ed. Chicago: American College of Surgeons; 98-117 (1997).
Farion, K.J., et al.,Changes in Red Cell Transfusion Practice among Adult Trauma Victims, J. Trauma, 44(4):583-587 (1998).
Baker, J.B., et al.,Type and Crossmatch of the Trauma Patient, J. Trauma, 50(5):878-881(May 2001).
DeFoe, G.R., et al.,Lowest Hematocrit on Bypass and Adverse Outcomes Associated with Coronary Artery Bypass Grafting, Ann Thorac Surg., 71:769-776 (2001).
Wu, W.C., et al.,Blood Transfusion in Elderly Patients with Acute Myocardial Infarction, New England Journal of Medicine, 345(17):1230-1236 (Oct. 2001).
Practice Guidelines for Blood Component Therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy, Anesthesiology 84(3):732-747 (Mar. 1996).
Consensus Conference. Perioperative Red Blood Cell Transfusion, JAMA 260(18): 2700-2703 (Nov. 1988).
Gould, S.A., et al.,Fluosol DA-20 As A Red Cell Substitute in Acute Anemia, New England Journal of Medicine, 314(26):1653-1656 (Jun. 1986).
Spence, R.K., et al.,Fluosol DA-20 in the treatment of severe anemia: Randomized, controlled study of 46 patients, Critical Care Medicine, 18(11):1227-1230 (Nov. 1990).
Spence, R.K., et al.,Is Hemoglobin Level Alone a Reliable Predictor of Outcome in the Severely Anemic Patient? The American Surgeon, 58(2):92-95 (1992).
Carson, J.L., et al.,Severity of Anaemia and Operative Mortality and Morbidity, Lancet 1(8588):727-729 (Apr. 1988).
Carson, J.L, et al.,Effect of anaemia and cardiovascular disease on surgical mortality and morbidity, Lancet, 348(9034):1055-1060 (Oct. 1996).
Viele, M.K., et al.,What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses, Transfusion 34(5):396-401 (1994).
Sehgal L.R., et al.,Polymerized pyridoxylated hemoglobin: A red cell substitute with normal oxygen capacity, Surgery 95:433-438 (1984).
Amberson, W.R., et al.,Clinical Experience with Hemoglobin-Saline Solutions, J. Applied Physiology, 1(7):469-489 (Jan. 1949).
Brandt, J.L., et al.,The Effects of Hemoglobin Solutions on Renal Functions in Man, Blood, 6:1152-1158 (1951).
Miller, J.H., et al.,The Effect of Hemoglobin on Renal Function in The Human, Journal of Clinical Investigation, 30:1033-1040 (Jul. 1951).
Savitsky, J.P., et al.,A clinical trial of stroma-free hemoglobin, Clinical Pharmacology Journal, 23(1):73-80 (Jan. 1978).
Carmichael, F.J., et al.,A phase I study of oxidized raffinose cross-linked human hemoglobin, Crit Care Med, 28(7):2283-2292 (2000).
Kasper, S.M., et al.,Effects of a Hemoglobin-Based Oxygen Carrier(HBOC-201)on Hemodynamics and Oxygen Transport in Patients Undergoing Preoperative Hemodiulution for Elective Abdominal Aortic Surgery, Anesth Analg, 83:921-927 (1996).
LaMuraglia, G.M., et al.,The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution, J. Vascular Surgery, 31(2):299-308 (Feb. 2000).
Sloan, E.P., et al.,Diaspirin Cross-Linked Hemoglobin(DCLHb)in the Treatment of Severe Traumatic Hemorrhagic Shock, JAMA 282:1857-1864 (Nov. 1999).
Gould, S.A., et al.,Clinical Utility of Human Polymerized Hemoglobin as a Blood Substitute afterAcute Ttrauma and Urgent Surgery, J. Trauma 43(2):325-332 (Aug. 1997).
Gould, S.A., et al.,The First Randomized Trial of Human Polymerized Hemoglobin as a Blood Substitute in Acute Trauma and Emergent Surgery, J Am Coll Surg 187(2):113-122 (Aug. 1998).
Vengelen-Tyler, V., American Association of Blood Banks Technical Manual. 13thed., Bethesda (MD): American Association of Blood Banks, p. 389-396 (1999).
Huston, P., et al.,Withholding Proven Treatment in Clinical Research, New England Journal of Medicine 345(12):912-914 (Sep. 2001).
Emanuel, E.J., et al.,The Ethics of Placebo-Controlled Trials- A Middle Ground, New England Journal of Medicine, 345(12):915-914 (Sep. 2001).
Carson, J.L, et al.,Mortality and morbidity in patients with very low blood counts who decline blood transfusion, Transfusion, 42:812-818 (Jul. 2002).
Reiner, A.P.,Massive Transfusion, Perioperative Transfusion Medicine, p. 351-364 (1998).
Weiskopf, R.B., et al.,Human Cardiovascular and Metabolic Response to Actue, Severe Isovolemic anemia, JAMA 279(3): 217-221 (Jan. 1998).
Wilkerson, D.K., et al.,Limits of cardiac compensation in anemic baboons, Surgery, 103(6):665-670 (1988).
Levy, P.S., et al.,Oxygen Extraction Ratio: A Valid Indicator of Transfusion Need in a Limited Coronary Vascular Reserve?J. Trauma 32(6):769-774 (Jun. 1992).
Schwartz, J.P., et al.,The Influence of Coronary Stenosis On Transfusion Need., Cardiothoracic Surgery, Surgical Forum XLIV:226-228 (1993).
Moss, G.S., et al.,Transport of Oxygen and Carbon Dioxide by Hemoglobin-Saline Solution in the Red Cell-Free Primate, Surg. Gynecol Obstet, 142:357-362 (Mar. 1976).
Frantantoni, J.C.,Points to consider on efficiacy evaluation of hemoglobin and perfluorocarbon based oxygen carriers, Transfusion 34(8):712-713 (1994).
Frantantoni, J.C.,Red Cell Subsitutes: Evolution of Approaches for Demonstrating Efficacy, Blood-substitutes—Present and Future Perspectives, Elsevier Science S.A., p. 33-39 (1998).
Intensive Care. Resuscitation. First Aid, Malyshev, V.D., Ed., Moscow, “Meditsina”, p. 142 (2000) (with translation).
Clinical Surgery, Condon, R., et al. Eds, pp. 204-208; pp. 433-434 (1998) (with translation).
DeWoskin Richard
Doubleday Marc
Gould Steven
Hides George
McDonnell & Boehnen Hulbert & Berghoff
Mohamed Abdel A
Northfield Laboratories, Inc.
Weber Jon
LandOfFree
Method for treating patients with massive blood loss does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating patients with massive blood loss, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating patients with massive blood loss will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3833316